CN1267291A - 新的n－取代的脲的法呢基蛋白转移酶抑制剂 - Google Patents
新的n－取代的脲的法呢基蛋白转移酶抑制剂 Download PDFInfo
- Publication number
- CN1267291A CN1267291A CN98808189A CN98808189A CN1267291A CN 1267291 A CN1267291 A CN 1267291A CN 98808189 A CN98808189 A CN 98808189A CN 98808189 A CN98808189 A CN 98808189A CN 1267291 A CN1267291 A CN 1267291A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydrogen
- alkyl
- tumor cells
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87704997A | 1997-06-17 | 1997-06-17 | |
| US08/877,049 | 1997-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1267291A true CN1267291A (zh) | 2000-09-20 |
Family
ID=25369144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98808189A Pending CN1267291A (zh) | 1997-06-17 | 1998-06-15 | 新的n－取代的脲的法呢基蛋白转移酶抑制剂 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0989979A1 (enExample) |
| JP (1) | JP2002506444A (enExample) |
| KR (1) | KR20010013881A (enExample) |
| CN (1) | CN1267291A (enExample) |
| AR (1) | AR013094A1 (enExample) |
| AU (1) | AU8253598A (enExample) |
| CA (1) | CA2293706C (enExample) |
| CO (1) | CO4940458A1 (enExample) |
| HU (1) | HUP0002954A3 (enExample) |
| IL (1) | IL133389A0 (enExample) |
| NZ (1) | NZ501571A (enExample) |
| PE (1) | PE82799A1 (enExample) |
| WO (1) | WO1998057948A1 (enExample) |
| ZA (1) | ZA985205B (enExample) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189456A (zh) * | 2013-03-15 | 2015-12-23 | 亚瑞克西斯制药公司 | Kras g12c的共价抑制剂 |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| US9810690B2 (en) | 2015-10-19 | 2017-11-07 | Araxes Pharma Llc | Method for screening inhibitors of Ras |
| US9840516B2 (en) | 2013-10-10 | 2017-12-12 | Araxes Pharma Llc | Substituted quinazolines as inhibitors of KRAS G12C |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US9926267B2 (en) | 2013-03-15 | 2018-03-27 | Araxes Pharma Llc | Covalent inhibitors of K-Ras G12C |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| US10111874B2 (en) | 2014-09-18 | 2018-10-30 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN111960990A (zh) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | 一种助剂及其制备方法 |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| MXPA03003011A (es) * | 2000-10-05 | 2003-07-14 | George Q Daley | Metodos para inducir muerte de celulas cancerosas y regresion de tumores. |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| WO2005058823A1 (ja) * | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| SK86198A3 (en) * | 1995-12-22 | 1999-02-11 | Schering Corp | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| TR199901275T2 (xx) * | 1996-09-13 | 1999-09-21 | Schering Corporation | Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler. |
| CZ87499A3 (cs) * | 1996-09-13 | 1999-08-11 | Schering Corporation | Substituované deriváty benzocykloheptapyridinu použitelné při léčbě nádorových onemocnění tím, že inhibují farnesylprotein transferázu |
-
1998
- 1998-06-15 WO PCT/US1998/011507 patent/WO1998057948A1/en not_active Ceased
- 1998-06-15 EP EP98932717A patent/EP0989979A1/en not_active Withdrawn
- 1998-06-15 JP JP50450299A patent/JP2002506444A/ja not_active Ceased
- 1998-06-15 AU AU82535/98A patent/AU8253598A/en not_active Abandoned
- 1998-06-15 CN CN98808189A patent/CN1267291A/zh active Pending
- 1998-06-15 ZA ZA985205A patent/ZA985205B/xx unknown
- 1998-06-15 IL IL13338998A patent/IL133389A0/xx unknown
- 1998-06-15 PE PE1998000506A patent/PE82799A1/es not_active Application Discontinuation
- 1998-06-15 CA CA002293706A patent/CA2293706C/en not_active Expired - Fee Related
- 1998-06-15 HU HU0002954A patent/HUP0002954A3/hu unknown
- 1998-06-15 NZ NZ501571A patent/NZ501571A/en unknown
- 1998-06-15 KR KR1019997011903A patent/KR20010013881A/ko not_active Withdrawn
- 1998-06-16 CO CO98034144A patent/CO4940458A1/es unknown
- 1998-06-16 AR ARP980102858A patent/AR013094A1/es unknown
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10273207B2 (en) | 2013-03-15 | 2019-04-30 | Araxes Pharma Llc | Covalent inhibitors of kras G12C |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| USRE50527E1 (en) | 2013-03-15 | 2025-08-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS G12C |
| CN105189456B (zh) * | 2013-03-15 | 2017-12-19 | 亚瑞克西斯制药公司 | Kras g12c的共价抑制剂 |
| US9926267B2 (en) | 2013-03-15 | 2018-03-27 | Araxes Pharma Llc | Covalent inhibitors of K-Ras G12C |
| US10919850B2 (en) | 2013-03-15 | 2021-02-16 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| CN105189456A (zh) * | 2013-03-15 | 2015-12-23 | 亚瑞克西斯制药公司 | Kras g12c的共价抑制剂 |
| US9840516B2 (en) | 2013-10-10 | 2017-12-12 | Araxes Pharma Llc | Substituted quinazolines as inhibitors of KRAS G12C |
| US10370386B2 (en) | 2013-10-10 | 2019-08-06 | Araxes Pharma Llc | Substituted quinolines as inhibitors of KRAS G12C |
| US10111874B2 (en) | 2014-09-18 | 2018-10-30 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| US10829458B2 (en) | 2015-04-10 | 2020-11-10 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| USRE50490E1 (en) | 2015-04-10 | 2025-07-15 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| US10351550B2 (en) | 2015-07-22 | 2019-07-16 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US9810690B2 (en) | 2015-10-19 | 2017-11-07 | Araxes Pharma Llc | Method for screening inhibitors of Ras |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10723738B2 (en) | 2016-09-29 | 2020-07-28 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| CN111960990A (zh) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | 一种助剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA985205B (en) | 1998-12-15 |
| AR013094A1 (es) | 2000-12-13 |
| CA2293706A1 (en) | 1998-12-23 |
| HUP0002954A3 (en) | 2002-11-28 |
| JP2002506444A (ja) | 2002-02-26 |
| CA2293706C (en) | 2008-11-18 |
| CO4940458A1 (es) | 2000-07-24 |
| PE82799A1 (es) | 1999-08-26 |
| WO1998057948A1 (en) | 1998-12-23 |
| AU8253598A (en) | 1999-01-04 |
| EP0989979A1 (en) | 2000-04-05 |
| KR20010013881A (ko) | 2001-02-26 |
| HUP0002954A2 (hu) | 2001-06-28 |
| NZ501571A (en) | 2002-02-01 |
| IL133389A0 (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1047776C (zh) | 具有药理学活性的吡啶类衍生物及其制备方法 | |
| CN1237165A (zh) | 法呢基蛋白转移酶的三环抑制剂 | |
| CN1496980A (zh) | 具有抗哮喘、抗过敏和免疫抑制/免疫调节作用的n-取代的吲哚-3-乙醛酰胺类化合物 | |
| KR20010013881A (ko) | 파네실 단백질 전이효소의 신규한 ｎ-치환된 우레아 억제제 | |
| CN1271355A (zh) | 杂环化合物和以其为有效成分的抗肿瘤剂 | |
| CN1639153A (zh) | 吲哚基马来酰亚胺衍生物 | |
| HUE032864T2 (en) | Substituted pyrrolidine-2-carboxamides | |
| CN1267289A (zh) | 用于抑制g－蛋白功能和治疗增生性疾病的羧基哌啶基乙酰胺三环化合物(法呢基蛋白转移酶抑制剂) | |
| CN1236365A (zh) | 用作法呢基－蛋白转移酶抑制剂的取代的苯并芳庚并吡啶 | |
| CN1495182A (zh) | 用于抑制细胞增殖的取代的双吲哚基马来酰亚胺 | |
| CN1237176A (zh) | 用作fpt抑制剂的三环化合物 | |
| CN1266433A (zh) | 用于抑制法呢基蛋白转移酶的苯并吡啶并环庚烷化合物 | |
| CN1119345C (zh) | 用作法呢基蛋白转移酶抑制剂的苯并(5.6)环庚并吡啶化合物 | |
| CN1187333C (zh) | 某些取代的己内酰胺、含有它们的药物组合物和它们在治疗肿瘤中的用途 | |
| CN1247584C (zh) | 1－[烷基]、1－[(杂芳基)烷基]和1－[(芳基)烷基]－7－吡啶基－咪唑并[1,2－a]嘧啶－5(1H)－酮衍生物 | |
| CN1113064C (zh) | 顺式取代氨基环丙烷衍生物 | |
| CN1267288A (zh) | 用作法呢基蛋白转移酶抑制剂的三环酮酰胺衍生物 | |
| CN1267297A (zh) | 用作法呢基蛋白转移酶抑制剂的苯并(5.6)环庚并吡啶环脲和内酰胺 | |
| CN1236364A (zh) | 用作法呢基蛋白转移酶抑制剂的取代的苯并芳庚并吡啶衍生物 | |
| CN1190971A (zh) | 三环性苯并氮杂䓬化合物 | |
| CN1777603A (zh) | 取代的2－(二氮杂－双环－烷基)－嘧啶酮衍生物 | |
| CN1267290A (zh) | 新的法呢基－蛋白转移酶的三环磺酰胺抑制剂 | |
| CN1155595C (zh) | 作为用于治疗癌症的抗增殖剂的取代的吡咯类化合物 | |
| CN1226246A (zh) | 用作法呢基蛋白转移酶抑制剂的新的三环n－氰亚胺类化合物 | |
| CN1229374C (zh) | 用于抑制细胞增殖的取代的二吲哚基马来酰亚胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |